Introduction
============

Picornaviruses are small, non-enveloped, positive-strand RNA viruses that infect diverse animal and human hosts ([@B22]; [@B28]). As one of the largest viral families, picornaviruses contain 31 genera and 54 species, including cardioviruses \[e.g., *encephalomyocarditis virus* (EMCV) and *Theiler's virus* (TEV)\], enteroviruses \[e.g., *enterovirus* 71 (EV71); *poliovirus* (PV); coxsackievirus (CV); and rhinovirus (RV)\], hepatitis A virus (HAV), and foot-and-mouth disease virus (FMDV) ([@B28]). Picornavirus genomes are single-stranded RNAs (7,000 to 9,000 nucleotides in length) which consist (from 5′ to 3′) of a 5′ untranslated region (UTR), a single open-reading frame (ORF), a 3′ UTR, and a poly(A) tail (Figure [1](#F1){ref-type="fig"}; [@B28]). The ORF is translated into a polyprotein, which is processed by viral proteases into structural proteins (VP1--VP4) and non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D pro, and in some genera, L pro). Structural proteins are used to assemble viral capsids whereas non-structural proteins replicate the genomic RNA in conjunction with cell proteins ([@B3]; [@B9]; [@B22]).

![The viral genome is a single-stranded(ss) RNA, encoding a single open reading frame (ORF), an untranslated region (UTR) at either terminus, and a poly(A) tail at the 3′ end. The ORF is translated as a polyprotein, which is processed by viral proteases to release the structural proteins (VP1-4) needed to assemble virus capsids, and the non-structural proteins (2A-2B-2C-3A-3B-3C-3D pro and in some genera Lpro).](fmicb-09-02943-g001){#F1}

Interferons (IFNs) which play important roles in regulation and activation of host immune responses, were first discovered by Isaacs and Lindenmann in 1950s ([@B41]; [@B46]). IFNs are classified into three categories according to their antiviral activities, genetic, structural and functional features and their cognate receptors ([@B65]): type I (IFN-α, IFN-β, IFN-δ, IFN-𝜀, IFN-ζ, IFN-κ, IFN-τ, and IFN-ω), type II (IFN-γ) ([@B46]), and type III (IFN-λ1 or IL-29, IFNλ-2 or IL-28A, IFNλ-3 or IL-28B, and IFN-λ4) ([@B87]; [@B30]). Type I IFNs typically have antiviral effects and are the most broadly expressed, well-known antiviral IFNs. Although type I IFNs can be secreted by most parenchymal cells, the main type I IFN producer is plasmacytoid dendritic cell (pDC) ([@B13]; [@B44]). Type II IFN is produced by activated T cells and NK cells and predominantly induce macrophage activation stimulating their activity against ingested intracellular non-viral pathogens ([@B13]). Type III IFNs are produced by epithelial cells, leukocytes, intestinal eosinophils and pDCs ([@B2]; [@B36]; [@B83]; [@B35]; [@B61]; [@B74]). Type III IFNs are similar to type I IFNs, and also play roles in regulating the host antiviral response ([@B84]; [@B44]).

Viruses develop various strategies to inhibit secretion of IFNs and promote viral replication inside host cells. Mounting evidence shows that infecting viruses can evade IFN response either by suppressing IFN production or by blocking IFN induction of interferon-stimulated gene factors (ISGs) ([@B113]; [@B29]). Viral non-structural proteases play an important role in this process. In this review, we summarize our current knowledge of the role of picornavirus non-structural proteases in antagonizing IFN induction via different signaling pathways to inhibit host antiviral responses.

Signaling Pathways Inducing IFN Production
==========================================

When viruses infect organisms, the host innate immune system detects the presence of pathogen-associated molecular patterns via host pattern recognition receptors (PRRs) ([@B97]; [@B13]). These include transmembrane PRRs such as Toll-like receptors (TLRs), cytosolic RIG-like RNA helicases such as melanoma differentiation-associated gene (MDA-5), retinoic acid induced gene-I (RIG-I), and other molecules ([@B6]; [@B106]). PRRs recruit a number of specific adaptor proteins to trigger a downstream signaling cascade and activate three major pathways to produce IFNs: the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) ([@B13]), the mitogen-activated protein kinase (MAPK), and the IFN regulatory factor (IRF) pathways ([@B1]; [@B37]). IFNs can signal in an autocrine or paracrine manner to induce hundreds of ISGs that fortify host defenses (Figure [2](#F2){ref-type="fig"}; [@B75]).

![The overview of picornavirus non-structural proteins suppress the production of IFNs. When viruses infect organisms, the host innate immune system detects the presence of pathogen-associated molecular patterns via host pattern recognition receptors, then recruit a number of specific adaptor proteins to trigger a signaling cascade leading to the establishment of an antiviral state based on IFN and proinflammatory cytokines induction. The green arrays represent observations that have yet to be associated with a specific mechanism of action of the production of IFNs. The scissors illustrate the inhibition of viral non-structural proteins in the production of IFNs.](fmicb-09-02943-g002){#F2}

Induced IFNs exert their activity by binding and activating IFN receptors. Type I IFN receptors are composed of interferon-α/β receptors 1 and 2 subunits (IFNAR1 and IFNAR2) ([@B68]). Type III IFNs receptors are composed of two different chains, the IFN-λR1 high-affinity chain and IL-10R2 low-affinity chain ([@B12]). The binding of type I IFNs with its receptor leads to the phosphorylation of Janus kinase1 (JAK1) and tyrosine kinase 2 (TYK2). These activated kinases then phosphorylate STAT1 and STAT2 and promote STAT1 and STAT2 heterodimerization. The resulting heterodimer interacts with IRF9 to form a heterotrimeric complex called interferon-stimulated gene factor 3 (ISGF3) ([@B73]). This complex then translocate to the nucleus and binds a 12--15 bp IFN-α/β-stimulated response element (ISRE' 5′-G/ANGλN2GλCT-3′), which regulates the transcription of over 300 IFN-stimulated genes, some of which lead to IFN-α and IFN-β expression (Figure [2](#F2){ref-type="fig"}). Type III IFNs have almost the same process with that of type I IFNs ([@B8]; [@B12]).

Type II IFN receptor is composed of two subunits, IFNGR1 and IFNGR2. After the binding of IFN-γ proteins to IFNGR, STAT1 homodimers is formed and bind to IFN-γ-activated site (GAS) enhancer elements with the help of the promoters of IFN-stimulated genes resulting in the production of genes encoding pro-inflammatory cytokines and apoptotic factors. Furthermore, IFN-γ can also activate STAT3 homodimers, which result in the production of pro-inflammatory cytokines and anti-inflammatory cytokines IL-10 ([@B30]).

In addition, macrophage recognition of virions induces the secretion of IL-12, IL-18 and other cytokines ([@B76]; [@B10]). IL-12 binds to the receptor complex consisting of IL12Rβ1 and IL12Rβ2, stimulating NK cells and instigating a signaling cascade that induces STAT4 phosphorylation leading to IFN-γ synthesis ([@B51]; [@B10]). IL-18 stimulates the full activity of NK cells to secrete IFN-γ in response to IL-12 stimulation ([@B63]; [@B56]).

Although type III and type I IFNs share many similarities in their promoter regions and binding sites for transcription factors ([@B69]; [@B90]), for instance, IFN-β and IFN-λ1/2/3 promoters contain IRF- and NF-kβ-binding sites; IFN-α promoters have IRF-binding sites ([@B42]; [@B21]; [@B84]), the expression of type III and type I IFNs is regulated through different mechanisms ([@B66]). For example, type III interferons are produced mainly by antigen-presenting cells and epithelial cells ([@B12]), while the major cell type responsible for type I IFN production is the pDC ([@B60]; [@B12]). Type I IFNs are induced by mitochondrial-associated MAVS, whereas type III IFNs are stimulated by peroxisome-associated MAVS ([@B67]). In addition, IRF1 plays a unique role in type III IFN induction while IRF3 and IRF7 play vital roles in type I IFN production ([@B70]).

Picornavirus Non-Structural Proteins Inhibit IFN Production to Counteract Host Antiviral Responses
==================================================================================================

While the host secretes IFNs to defense against viral infection, viruses have also developed effective immune evasion mechanisms to counteract the host's antiviral responses. Numerous studies have demonstrated that picornavirus proteases can cleave adaptors, receptors and regulators involved in the signaling pathways controlling IFN induction to inhibit production of type I IFNs ([@B101]; [@B50]). Besides, picornavirus non-structural proteins play important roles in the suppression of IFNs by down-regulating host gene expression and blocking the secretory pathway (Table [1](#T1){ref-type="table"}). However, in some picornaviruses, cooperation between non-structural proteins leads to inhibition of IFN induction ([@B92]; [@B11]).

###### 

Main signaling pathways in suppressing the production of IFNs of non-structural proteins in some picornaviruses.

  Non-structural Proteases   Virus                   Involved signaling pathways/structure                                                                                                                                                                              Type of IFN                 Reference
  -------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------- -----------------------
  Lpro                       FMDV                    Cleaving eIF4G, shutting off host cap-dependent mRNA translation, limiting the synthesis of host proteins                                                                                                          Type I IFNs                 [@B17]; [@B7]; [@B14]
                                                     Degrading NF-κB subunit p65/RelA, ubiquinating RIG-I, TBK1, and TRAF3/6, decreasing IRF-3/7, inhibiting NF-κB                                                                                                      IFN-β                       [@B15]; [@B102]
                                                     Via Lpro's catalytic activity and SAP domain                                                                                                                                                                       IFN-λ1                      [@B102]
                                                     Disrupting NF-κB and IRF via RIG-I/MDA5                                                                                                                                                                            IFN-λ1                      [@B91]; [@B102]
                             EMCV                    Lpro hinge domain interacting with Ran and disrupting the Ran GDP-GTP gradient, inhibiting nucleocytoplasmic transport                                                                                             Unclear                     [@B77]; [@B57]; [@B5]
                                                     Interfering IRF3                                                                                                                                                                                                   IFN-α/β                     [@B34]
                             TMEV                    Inhibiting IRF-3 dimerization                                                                                                                                                                                      IFN-β                       [@B93]
  2A                         EV71                    Cleaving MAVS and MDA5, preventing IRF3 phosphorylation                                                                                                                                                            Type I IFNs                 [@B27]
                                                     Inhibiting induction of downstream IFN-stimulated genes, the detailed mechanism is controversial                                                                                                                   Unclear                     [@B55]; [@B54]
                                                     Downregulating KPNA1, reducing formation of the STAT/karyopherin-α1 (KPNA1) complex                                                                                                                                Unclear                     [@B100]
                                                     Reducing serine phosphorylation of STAT1 and inactivating extracellular signal-regulated kinases                                                                                                                   IFN-γ                       [@B62]
                             RV                      Cleaving MAVS                                                                                                                                                                                                      Unclear                     [@B64]
                             CVB3/PV                 Cleaving MAVS and MDA5                                                                                                                                                                                             Type I IFNs                 [@B27]
  2B                         HAV                     Influencing MAVS function                                                                                                                                                                                          IFN-β                       [@B4]
                                                     Interfering TBK1/IKK𝜀 kinase complex, inhibiting RIG-I/MDA-5 and IRF3                                                                                                                                              IFN-β                       [@B72]
  2C                         EV71                    Inhibiting IKKβ phosphorylation and NF-κB activation via PP1 binding NF-κB                                                                                                                                         Unclear                     [@B112]; [@B53]
                                                     Suppressing p65/p50 dimerization by competing p65 IPT domain, suppressing the activation of NF-κB                                                                                                                  Unclear                     [@B19]
                             CVA16/CVB3              Inhibiting IKKβ phosphorylation and NF-κB activation via PP1 binding                                                                                                                                               Unclear                     [@B72]; [@B19]
  3A                         FMDV                    Reducing expression of MDA5, RIG-I and VISA by decreasing their mRNA levels, inhibiting RLR pathway                                                                                                                IFN-β                       [@B52]
  3C                         EV71                    Cleaving TRIF and TBK1, inhibiting TLR3 and RIG-I, preventing activation of IRF3 and IRF7                                                                                                                          IFN-β                       [@B48]
                                                     Inhibiting IRF7 and IRF9                                                                                                                                                                                           Type I IFNs                 [@B40]; [@B50]
                                                     Cleaving TAK1/TAB1/TAB2/TAB3 complex, NF-κB                                                                                                                                                                        Unclear                     [@B47]
                                                     Binding with RIG-I, impairing RIG-I's interaction with MAVS                                                                                                                                                        Type I IFNs                 [@B108]
                             CV-A16, CV-A6, EV-D68   Cleaving TAK1 to inhibit the NF-κB response                                                                                                                                                                        Unclear                     [@B86]
                                                     Binding with MDA5, inhibiting the interaction with MAVS                                                                                                                                                            Type I IFNs                 [@B86]
                             CVB3                    Cleaving MAVS and TRIF                                                                                                                                                                                             Type I IFNs                 [@B64]
                             EMCV                    Cleaving TANK, disrupting the formation of the TANK--TBK1--IKK𝜀--IRF3 tetramer, decreasing TBK1- and IKK𝜀-mediated IRF3 phosphorylation, impairing the ability of TANK to inhibit TRAF6-mediated NF-κB signaling   Type I IFNs                 [@B38], [@B39]
                                                     Blocking formation of SG                                                                                                                                                                                           Unclear                     
                                                     Cleaving IRF3-5D, inhibits JAK-STAT signaling                                                                                                                                                                      Type I IFNs                 
                                                     Suppressing STAT1 or IRF3 binding to the IFN-β promoter                                                                                                                                                            Type I IFNs                 
                             FMDV                    Cleaving NEMO                                                                                                                                                                                                      Unclear                     [@B111]
                                                     Cleaving TANK, generating a 15-kDa N-terminal fragment and impairing TANK's ability to suppress TRAF6-mediated NF-κB signaling                                                                                     Unclear                     [@B26]
                                                     Suppressing IRF3 by degrading autophagy-related protein ATG5-ATG12                                                                                                                                                 Unclear                     [@B26]
                                                     Degrading KPNA1, blocking STAT1/STAT2 nuclear translocation                                                                                                                                                        Unclear                     [@B20]
                             SVV                     Cleaving MAVS, TRIF, and TANK                                                                                                                                                                                      Type I IFNs                 [@B79]
                                                     Reducing the expression of IRF3 and IRF7 and phosphorylating them                                                                                                                                                  IFN-α1, IFN-α4, and IFN-β   [@B109]
                             HAV                     Cleaving MAVS                                                                                                                                                                                                      Type I IFNs                 [@B110]
                                                     Cleaving NEMO                                                                                                                                                                                                      Unclear                     [@B103]; [@B108]
                                                     Inhibiting NF-κB activation through cleavage of the TAK1/TAB1/TAB2/TAB3 complex                                                                                                                                    Unclear                     [@B50], [@B47]
  3ABC                       HAV                     Cleaving MAVS and disrupts activation of IRF3 through the RLR pathway                                                                                                                                              Unclear                     [@B110]; [@B16]
  3CD                                                Disrupting RIGI/MDA5, inhibiting dimerization of IRF-3 and translocation of IRF-3 to the nucleus                                                                                                                   IFN-β                       [@B81]
  3D                         EV71                    Attenuating STAT1 tyrosine phosphorylation                                                                                                                                                                         IFN-γ                       [@B104]
                                                                                                                                                                                                                                                                                                    

Lpro
----

### Lpro of FMDV

Foot-and-mouth disease virus Lpro is a kind of papain-like cysteine protease, which was first identified by [@B94]. FMDV's RNA genome encodes a polyprotein, Lpro is located near its N-terminus (residue ∼2330) and there are two forms of FMDV Lpro, Laboratory (201 aa) and Lb (173 aa) ([@B45]). FMDV infection selectively induces IFN-α1 mRNA, and IFN-β mRNA levels become elevated only after a significant duration of infection (24 h) ([@B14]). By inhibiting IFN production (including type I and type III IFNs) at the transcriptional and translational levels, FMDV Lpro down regulates the host innate immune response to FMDV infection. FMDV Lpro can repress IFN-β transcription by reducing IFN-stimulated gene products ([@B52]) decreasing IFN-β mRNA levels during early infection and inhibiting activation of NF-κB via degradation of the NF-κB subunit p65/RelA and ubiquitination of RIG-I, TBK1, and TRAF3/6, resulting decreased IRF-3/7 protein expression ([@B15]; [@B102]). Additionally, Lpro contributes to induce the cleavage of host eukaryotic translation initiation factor 4γ (eIF4G) ([@B17]; [@B7]), shutting off host cap-dependent mRNA translation, thus limiting the synthesis of host proteins ([@B14]), which may possibly include type I IFNs.

Foot-and-mouth disease virus Lpro also antagonizes IFN-λ1: Lpro's catalytic activity and SAP domain are involved in the suppression of IFN-λ1 induction ([@B102]). In addition, by disrupting activation of NF-κB and IRFs and inhibiting IFN-λ1 expression induced by RIG-I/MDA5, FMDV Lpro inhibits IFN-λ1 promoter activation ([@B102]).

### Lpro of Cardiovirus

Cardiovirus polyproteins begin with short N-terminal Leader (L) sequences, EMCV Lpro (∼67 residues) and TMEV Lpro (∼76 residues) contains common zinc-finger and acidic domains. Although cardiovirus Lpro is different from FMDV Lpro and does not function as a protease, it represses IFN-α/β synthesis during viral infection. In eukaryotes, nucleocytoplasmic transport of RNA and protein relies on the Ran-GTPase system. EMCV Lpro directly interacts with Ran and disrupts the RanGDP-GTP gradient leading to inhibition of nucleocytoplasmic transport ([@B77]; [@B57]), suppressing the production of IFN. EMCV Lpro hinge domain plays a major role in the interaction with Ran GTPase ([@B5]). EMCV Lpro interferes with the transactivation function of IRF3 suppressing IRF3-mediated IFN-α/β production ([@B34]). Studies have demonstrated that TMEV Lpro can block the production of type I IFN at the transcriptional level ([@B98]), this transcriptional inhibition is correlated with inhibition of IRF-3 dimerization ([@B85]).

2A
--

### 2A of Enteroviruses

Enteroviruses 2A has protease activity ([@B82]), which can not only process the viral polyprotein ([@B96]), but also cleave a variety of host proteins and inhibit the host translation whose function is quite similar to Lpro in FMDV.

*Enterovirus* 71 2A cleaves MAVS from the outer membrane of mitochondria. The cleaved fragments are released into the cytoplasm where they effectively inactivate downstream signaling and cleave MDA5, thus preventing IRF3 phosphorylation, down regulating production of type I IFNs and increasing viral replication (as it was shown in Figure [2](#F2){ref-type="fig"}; [@B99]). During this process, EV71 2A cleaves at MAVS residues Gly209, Gly251, and Gly265, with a strong preference for cleavage at Gly251 ([@B99]). Similarly, Rhinovirus 2A inhibits the production of IFN by cleaving MAVS ([@B64]). CVB3 (coxsackievirus B3) 2A and poliovirus (PV) also mediate the cleavage of MAVS and MDA5, exerting the same functions in inhibiting type I IFNs ([@B27]).

*Enterovirus* 71 can still inhibit induction of downstream IFN-stimulated genes, although the mechanisms of EV71 disruption of IFN signaling have been controversial. [@B55] reported that EV71 2A acted as an IFN antagonist and that its protease activity was required for reduction of IFNAR1 levels. By reducing IFNAR1, EV71 inhibits IFN-mediated phosphorylation of Tyk2, Jak1, STAT1, and STAT2. However, [@B54] reported that EV71 infection down regulated expression of JAK1 but did not modify expression of IFNAR1. KPNA1 is a nuclear localization signal receptor for p-STAT1. A recent study reported that EV71 infection down regulated expression of KPNA1, reducing the formation of STAT/karyopherin-α1 (KPNA1) complex and resulting reduction of the IFN ([@B100]).

*Enterovirus* 71 2A attenuates IFN-γ signaling using a mechanism that is different from type I IFNs. 2A can suppress IFN-γ signaling by reducing serine phosphorylation of STAT1 and inactivating extracellular signal-regulated kinases without affecting STAT1 expression ([@B104]). EV71 2A alters signal transduction of type II IFNs without affecting the protein expression of IFN-γ.

Other genera picornaviruses, such as EMCV, do not encode 2A proteinase. They are sensitive to IFN and are unable to replicate in IFN-pretreated cells. Their 2A might not have function on evading the host immune response ([@B62]).

2B
--

### 2B of HAV

Hepatitis A virus 2B is a peripheral membrane protein, its coding region has variants ([@B25], [@B23], [@B24]), which makes it significantly larger than 2B in other picornaviruses. HAV 2B was found in close vicinity to the tubular interconnected network of mitochondrial membranes through its ability induce membrane rearrangements resulting in the influence of the production of IFNs ([@B31]). HAV 2B suppresses MAVS signaling more effectively with the cooperation of HAV 3ABC ([@B4]). HAV 2B appears to influence MAVS function without directly affecting the antigenic structure of MAVS ([@B72]); it also interferes with the TBK1/IKK𝜀 kinase complex. Consequently, RIG-I/MDA-5-mediated activation is inhibited and inhibition of IRF-3 signaling results in efficient suppression of IFN-β synthesis ([@B72]).

2C
--

### 2C of Enteroviruses

Enteroviruses 2C (329 aa and 37.5 kDa), such as EV71 and CVA16 2C ATPase, is not only an RNA helicase but also an ATP-independent RNA chaperone, which is critical for RNA replication and viability of enteroviruses ([@B107]; [@B32]). EV71 2C is localized both to the cytoplasm and the nucleus. EV71 2C interacts with protein phosphatase 1 (PP1) catalytic subunit through PP1-docking motifs (residues 1 to 47) located near the N-terminus of EV71 2C. Interactions with IKKβ are formed through a motif (residues 105 to 121) located within N-terminal region of EV71 2C, resulting in formation of a complex between PP1 and IKKβ ([@B53]). PP1 binding is crucial for EV71 2C-mediated inhibition of IKKβ phosphorylation. EV71 2C-mediated PP1 recruitment inhibits IKKβ phosphorylation, NF-κB activation and NF-κB signaling pathway-induced IFN production ([@B112]; [@B53]). Other enteroviruses, such as PV, coxsackie A virus 16 (CVA16), and coxsackie B virus 3 (CVB3) also exploit this mechanism to inhibit the production of IFN ([@B53]).

Additionally, EV71 2C (residues 105--125 and 126--263) is capable to suppress p65/p50 dimerization by competing p65 IPT domain in association with p50, suppressing the activation of NF-κB and IFN ([@B19]).

3A
--

### 3A of FMDV

Foot-and-mouth disease virus 3A is a partially conserved protein, it has no homologous sequence to any other known proteases, which is unique among the picornaviruses. A recent study revealed that FMDV 3A down regulates FMDV-associated IFN-β induction via FMDV 3A inhibition of RLR-mediated IFN-β induction ([@B52]). Residues 103--153 near 3A's N-terminus interact with MDA5, RIG-I and VISA, and a 102-residue region near the N-terminus mediates inhibition of the IFN-β signaling pathway ([@B52]). FMDV 3A reduces expression of MDA5, RIG-I and VISA by decreasing their mRNA levels ([@B52]). This finding not only reveals a novel mechanism of FMDV 3A-mediated evasion of host innate immunity but also provide a new thought to explore this kind of non-structural proteins in other picornaviruses.

3C
--

Picornavirus 3C is a unique cysteine protease that combines features of both serine and cysteine proteases ([@B18]). Although 3C has similar spatial structures among all picornaviruses, and can inhibit IFN expression through similar pathways, including the NF-κB, Jak/STAT and IRF pathways, its specific sites of action are different.

### 3C of Enteroviruses

*Enterovirus* 71 3C is one of the most common functional proteins, which has been most widely studied in enteroviruses. EV71 3C inhibits induction of IFN by RIG-I or TLR3 and prevents activation of IRF3 and IRF7. Upon viral infection, TLR3 recruits TRIF (TIR domain-containing adaptor inducing IFN-β) and TBK1, which phosphorylate IRF3 and IRF7 ([@B48]). The TRIF Q312--S313 junction is critical for its cleavage by EV71 3C. EV71 3C-induced TRIF cleavage blocks IFN-β and NF-κB activation by TRIF ([@B49]). EV 71 3C can directly inhibit IRF7 and IRF9, repressing type I IFN production ([@B40]; [@B50]). EV71 3C protease activity is necessary to cleave IRF7. EV71 3C cleaves IRF7 at the Q189--S190 junction, yielding two fragments that are unable to stimulate IFN production ([@B50]).

Likewise, EV71 3C reduces IFN production by inhibiting activation of NF-κB ([@B47]). Transforming growth factor-β-activated kinase 1 (TAK1), TAK1-binding protein (TAB)1, TAB2, and TAB3 are all required for activation of downstream NF-κB. In mammalian cells, TAK1 binds to TAB1, forming TAK1-TAB1 complex. Thereafter, TAB2 and TAB3 are recruited to TAK1-TAB1 complex forming TAK1/TAB1/TAB2/TAB3 complex. This complex activates p38, IKKαβ![](fmicb-09-02943-i001.jpg) and c-Jun N-terminal kinase (JNK), thus inducing IFN production ([@B47]). EV71 3C cleaves TAK1 at the Q360--S361 junction yielding smaller products of about 30 kDa. The TAB1 Q414--G415 and Q451--S452 junctions are EV71 3C cleavage sites; cleavage results in about 45 kDa and 50 kDa products. EV71 3C cleaves TAB2 at the Q113--S114 junction. EV71 3C cleaves TAB3 at the Q173--G174 and Q343--G344 junctions, resulting in about 45 kDa and 60 kDa products. Cleavage disrupts the TAK1/TAB1/TAB2/TAB3 complex and reduces IFN production. It should be noted that TAB2 has NF-κB-activating function, but cleavage by EV71 3C impairs this activity ([@B47]). On the other hand, CVA-16, CV-A6, and EV-D68 3C cleave TAK1 to inhibit the NF-κB response ([@B86]).

Upon viral infection, EV71 3C can directly bind to RIG-I, impairing RIG-I's interaction with MAVS and inhibiting RIG-I-mediated type I IFN responses. It has been reported that ubiquitination of RIG-I is controlled by a tumor suppressor called CYLD ([@B108]). CYLD is a target of miR-526a, a potent IFN-β inducer, and miR-526a upregulation during viral infection is partially mediated by IRF7. By suppressing CYLD expression, miR-526a positively regulates VSV-associated type I IFN production. EV71 3C inhibits production of type I IFN by blocking miR-526a upregulation and CYLD downregulation.

CV-A16, CV-A6, and EV-D68 3C can bind to MDA5 and inhibit the interaction with MAVS, thus blocking the production of type I IFN ([@B86]). CVB3 3C also cleaves MAVS and Toll/IL-1 receptor domain-containing adaptor inducing interferon-beta (TRIF) at specific sites and inhibits the induction of type I IFN ([@B64]).

### 3C of EMCV

*Encephalomyocarditis virus* 3C is the only cysteine protease encoded by the viral genome, and it has a high degree of substrate specificity, besides Lpro, EMCV 3C is another antagonist. TANK is an NF-κB activator, TRAF6 serves as a platform to recruit the IKK complex and kinase TAK1, and TANK negatively regulates this function ([@B71]). EMCV 3C can cleave TANK at Gln291 and Gln197 ([@B38]), disrupting formation of the TANK--TBK1--IKK𝜀--IRF3 tetramer, decreasing TBK1- and IKK𝜀-mediated IRF3 phosphorylation, impairing the ability of TANK to inhibit TRAF6-mediated NF-κB signaling, and reducing type I IFN production ([@B38], [@B39]). SG is the location for efficient interaction between viral RNA and RLRs; EMCV 3C can also block formation of SG to inhibit activation of IFN genes ([@B39]). By cleaving IRF3-5D and other key proteins, EMCV 3C inhibits JAK-STAT signaling, suppressing type I IFN production ([@B39]). EMCV 3C may also suppress STAT1 or IRF3 binding to the IFN-β promoter to inhibit type I IFN production ([@B39]).

### 3C of FMDV

Foot-and-mouth disease virus 3C plays important roles in disrupting the translational system of the host and can negatively regulate innate immune signaling by degrading essential molecules in different pathways ([@B58]). FMDV 3C has the ability to cleave NEMO at Gln383 ([@B111]); cleavage impairs NEMO-mediated IFN production and its ability to act as a signaling adaptor in the RIG-I/MDA5 pathway ([@B101]). Moreover, FMDV 3C cleaves TANK, generating a 15-kDa N-terminal fragment and impairing TANK's ability to suppress TRAF6-mediated NF-κB signaling ([@B26]).

Under normal conditions, ATG5-ATG12 promotes activation of IRF3 and phosphorylation of TBK1 by preventing TRAF3 degradation, resulting in enhanced expression of IFN-β ([@B26]). FMDV suppresses IRF3 by degradation of autophagy-related protein ATG5-ATG12 to attenuate production of IFN via 3C ([@B26]).

Karyopherin α1 (KPNA1) is the nuclear localization signal receptor for STAT1. FMDV 3C interferes with the JAK-STAT signaling pathway by degrading KPNA1, blocking STAT1/STAT2 nuclear translocation and inhibiting IFN signaling ([@B20]).

### 3C of SVV

Seneca Valley virus (SVV) is most closely related to *Cardiovirus* ([@B33]). SVV 3C has a conserved catalytic box with His and Cys residues ([@B80]), which is similar to FMDV Lpro. SVV 3C can inhibit the production of type I IFN by directly cleaving MAVS, TRIF, and TANK ([@B80]). In addition, a recent result indicates that SVV 3C reduces the expression of IRF3 and IRF7 and phosphorylates them and then blocks the transcription of IFN-β, IFN-α1, IFN-α4, and ISG54 ([@B109]).

### 3C of HAV

Hepatitis A virus 3C is a cysteine proteinase which is responsible for most cleavages within the viral polyprotein ([@B88], [@B89]). HAV 3C cleaves MAVS at Gln428 to inhibit type I IFN production ([@B110]). Similar to FMDV 3C, HAV 3C also cleaves NEMO, impairing NEMO-mediated IFN production and its ability to act as a signaling adaptor in the RIG-I/MDA5 pathway ([@B103]; [@B108]). Moreover, HAV 3C inhibits NF-κB activation through cleavage of the TAK1/TAB1/TAB2/TAB3 complex, inhibiting the induction of IFNs ([@B50], [@B47]).

### 3ABC and 3CD of HAV

Processing intermediate HAV 3ABC and 3CD are both unique and have proteolytically activities in particle assembly ([@B78]). HAV 3ABC is a precursor cysteine protease. 3ABC cleaves MAVS and disrupts activation of IRF3 through the RLR pathway in mitochondria ([@B110]; [@B16]). With the help of the transmembrane domain of 3A, 3ABC localizes to mitochondria. MAVS cleavage also requires the protease activity of 3C ([@B110]). This feature of 3ABC is unique among picornaviruses.

Hepatitis A virus 3CD is the processing intermediate of 3ABCD. HAV 3CD disrupts RIGI/MDA5, inhibits dimerization of IRF-3 and translocation of IRF-3 to the nucleus, and impairs IFN-β promoter activation ([@B81]).

3D
--

### 3D of EV71

*Enterovirus* 71 3D is a kind of RNA-dependent RNA polymerase ([@B43]; [@B95]). [@B104] found that without interfering with IFN-γ receptor expression, EV71 3D can attenuate STAT1 tyrosine phosphorylation resulting in defective IFN-γ signaling. The detailed signaling pathway how 3D regulate STAT1 need further investigation, [@B104] guess that the function of EV71 3D may similar to EV71 2A, as a viral factor for immune-editing.

Outlook
=======

The interactions between picornaviruses and host defenses are complex and diverse. Moreover, viruses have developed multiple strategies to evade the host's innate immune system. To date, some of these strategies have been uncovered and significant progress has been achieved in understanding signaling pathways related to immune evasion. For example, the mechanism underlying inhibition by some non-structural proteins of IFN production in picornaviruses have been well studied. However, what we know today just represent a drop in the bucket, and we still need to understand the viral strategies involved in antagonizing the host's innate immune system. For example, SVV 3C has similar conserved catalytic box and similar function to FMDV Lpro in antagonizing the innate immune response and whether SVV 3C has other similar function to FMDV Lpro need further research. In addition, there are many similarities between different genera of picornaviruses. However, further efforts should be made to explore key mechanisms underlying inhibition by some non-structural proteins of IFN production, such as 2B, 2C, 3A, and 3D, across all picornavirus.

Recently, it has been discovered that some picornaviruses only cause an acute and self-limiting infection without major pathogenesis in hosts requiring more research on therapeutic approach ([@B105]; [@B59]). The role of non-structural proteins in such picornaviruses may make contributions to better understand not only the therapeutic antiviral activity of IFNs, but also may reveal how these proteins (with or without protease activities) influence and control the IFN signaling transduction *in vivo*.
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